AIM: To study the cytokines regulated downstream effecter cyclooxygenase (COX-2's) function in the progression of serious hepatitis. METHODS: Samples from 75 patients with hepatitis B virus (HBV)-associated serious liver disease with well-characterised clincal profiles and 30 HBV-infected patients were assessed by ELISA. RESULTS: Compared with the general HBV-infected patients, serum TXB2 and 6-keto-PG1α level were uniformly elevated in all serious hepatitis patients (acute serious hepatitis patients vs general HBV-infected patients (P < 0.001); sub-acute serious hepatitis patients vs general HBV-infected patients (P < 0.01); chronic serious hepatitis patients vs general HBV-infected patients (P < 0.001). But there were no significant difference of these cytokines levels among the different types of serious hepatitis patients (P > 0.05). CONCLUSION: In conclusion, product of COX-2 metabolism TXB2 and 6-keto-PGF1α were associated with the clinical progression of serious hepatitis; especially TXB2/6-keto-PGF1α ratio is an effective biological marker for prognosis and diagnosis for serious hepatitis.
AIM: To study the cytokines regulated downstream effecter cyclooxygenase (COX-2's) function in the progression of serious hepatitis. METHODS: Samples from 75 patients with hepatitis B virus (HBV)-associated serious liver disease with well-characterised clincal profiles and 30 HBV-infectedpatients were assessed by ELISA. RESULTS: Compared with the general HBV-infectedpatients, serum TXB2 and 6-keto-PG1α level were uniformly elevated in all serious hepatitispatients (acute serious hepatitispatients vs general HBV-infectedpatients (P < 0.001); sub-acute serious hepatitispatients vs general HBV-infectedpatients (P < 0.01); chronic serious hepatitispatients vs general HBV-infectedpatients (P < 0.001). But there were no significant difference of these cytokines levels among the different types of serious hepatitispatients (P > 0.05). CONCLUSION: In conclusion, product of COX-2 metabolism TXB2 and 6-keto-PGF1α were associated with the clinical progression of serious hepatitis; especially TXB2/6-keto-PGF1α ratio is an effective biological marker for prognosis and diagnosis for serious hepatitis.